EarlyHealth Group partners with Ideogen to support an Early Access Program (EAP) on Beliodaq®.

We are happy to share that this summer EarlyHealth Group has signed a collaboration agreement with Ideogen Group, a pharmaceutical company based in Switzerland, in efforts to make Beliodaq® (belinostat) accessible to patients in Europe. The drug is indicated in the treatment of a rare type of cancer called peripheral T-cell lymphoma in refractory or relapsed patients.

This Histone Deacetylase (HDAC) Inhibitor has been approved for use by the FDA in the United States as part of an accelerated approval process and is only available outside the US through “special access programs”. EarlyHealth Group, with a consolidated presence in several countries in Europe, will assist Ideogen in ensuring this treatment is made available in Spain. EarlyHealth will focus on supporting patients and doctors accessing Beliodaq® through the Spanish government’s special medicines use program, formerly called compassionate use program.

It’s a privilege for our Group to strengthen our partnership with Ideogen, especially when the shared objective is improving patients’ lives by enabling access to drugs not marketed or locally unavailable.